---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-016562"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:09:32.000793+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wellgistics prices $5M offering (7.14M shares + warrants at $0.70), partners with TheracosBio on Brenzavvy

## Summary
- Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.
- Offering closed Sept 29; H.C. Wainwright acted as placement agent, receiving $350K fee and 500K warrants at $0.875.
- Company to use net proceeds for working capital, R&D, and potential acquisitions.
- Strategic collaboration with TheracosBio to distribute diabetes drug Brenzavvy (bexagliflozin) via 6,500+ pharmacies starting Q4 2025.
- Partnership aims to lower patient costs by bypassing PBMs; Q4 rollout expected to generate near-term revenue.

## SEC filing metadata
- accession: 0001493152-25-016562
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315225016562/0001493152-25-016562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315225016562/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-016562
- JSON: https://secwatch.observer/filing/0001493152-25-016562.json
- Plain text: https://secwatch.observer/filing/0001493152-25-016562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.